Vial cracking causes halt in lupus drug trial

Cracked vials have led to the suspension of a clinical trial. Biotech drug developer Anthera found the cracks in vials of its experimental lupus drug, A-623, which is in Phase IIb testing.

The company announced Tuesday that it has suspended dosing and enrollment in the trial while it investigates.

Faulty vials were discovered by a clinical investigator at one of the trial sites. Upon investigation, the company found additional cracked vials in the drug storeroom of another facility. CEO Paul Truex says in a release that he's committed to resolving the issue and discussing plans with the FDA.

- see the Anthera release


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.